2005-03-01
Effects of tamoxifen and octreotide LAR on the IGF-system compared with tamoxifen monotherapy
Publication
Publication
European Journal of Cancer , Volume 41 - Issue 5 p. 694- 701
The insulin-like growth factor (IGF)-system was evaluated in 150 breast cancer patients participating in a randomised phase III trial comparing octreotide pamoate and tamoxifen with tamoxifen + placebo. Alterations in the IGF-system in the two treatment arms and individual changes with respect to outcome were compared. Serum IGF-I and -II, free IGF-I, and insulin-like growth factor binding protein 1-3 (IGFBP1-3) were measured by radioimmmunoassay (RIA)/immunoradiometric assay (IRMA) and IGFBPs by Western ligand blots (WLB) before and during treatment. Combined treatment caused a higher increase in IGFBP-1 and larger suppression of total and free IGF-I, IGF-II, and IGFBP-3 (P < 0.01 for all), but less suppression of IGFBP-2 (P < 0.05) compared with tamoxifen monotherapy. An increase in IGFBP-2 ≥25% was associated with decreased progression-free survival (PFS) in the total patient population and combined treatment group. Similar response rates and time to progression in the treatment arms suggests moderate suppression of circulating IGF-I has no influence on clinical outcome.
Additional Metadata | |
---|---|
, , , , | |
doi.org/10.1016/j.ejca.2004.12.015, hdl.handle.net/1765/73709 | |
European Journal of Cancer | |
Organisation | Department of Medical Oncology |
Helle, S., Mietlowski, W., Guastalla, J. P., Szakolczai, I., Bajetta, E., Sommer, H., … Lønning, P. (2005). Effects of tamoxifen and octreotide LAR on the IGF-system compared with tamoxifen monotherapy. European Journal of Cancer, 41(5), 694–701. doi:10.1016/j.ejca.2004.12.015 |